Company / Cost of Revenue
Aurinia Pharmaceuticals Inc. Cost of Revenue History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$32.7M
FY2025
5-year range
$0 / $32.7M
FY2021-FY2025
Trend
+15.6%
vs FY2024
Sector context
#59 of 85
Health Care
What the data says
At $33M, Aurinia Pharmaceuticals Inc.'s cost of revenue ranks #27 of 85 in the Health Care sector. Cost of Revenue has increased for 3 consecutive years, from $0 in FY2022 to $33M in FY2025.
Based on SEC 10-K filings.
$33M in FY2025.
Increased from $14M to $33M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#27 of 85 in Health CareTop 31% of 85This company $32.7M Sector average $2.0B
▼
-98.4% below sector average
Key checks
Key Insights
- In FY2025, cost of revenue increased 15.6% year-over-year.
- Ranks #59 out of 85 companies in the Health Care sector.
- Lowest cost of revenue in the period was in FY2022.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $32.7M | +15.6% |
| FY2024 | $28.2M | +99.7% |
| FY2023 | $14.1M | - |
| FY2022 | $0 | - |
| FY2021 | $0 | - |
| FY2020 | $0 | - |
| FY2019 | $0 | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026